KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Cash & Equivalents (2016 - 2025)

Cvs Health (CVS) has disclosed Cash & Equivalents for 17 consecutive years, with $8.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 1.55% year-over-year to $8.5 billion, compared with a TTM value of $8.5 billion through Dec 2025, down 1.55%, and an annual FY2025 reading of $8.5 billion, down 1.55% over the prior year.
  • Cash & Equivalents was $8.5 billion for Q4 2025 at Cvs Health, down from $9.1 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $17.2 billion in Q3 2022 and bottomed at $5.6 billion in Q1 2021.
  • Average Cash & Equivalents over 5 years is $10.5 billion, with a median of $9.8 billion recorded in 2021.
  • The sharpest move saw Cash & Equivalents crashed 52.12% in 2021, then surged 75.02% in 2022.
  • Year by year, Cash & Equivalents stood at $9.4 billion in 2021, then surged by 37.6% to $12.9 billion in 2022, then crashed by 36.69% to $8.2 billion in 2023, then increased by 4.76% to $8.6 billion in 2024, then dropped by 1.55% to $8.5 billion in 2025.
  • Business Quant data shows Cash & Equivalents for CVS at $8.5 billion in Q4 2025, $9.1 billion in Q3 2025, and $11.8 billion in Q2 2025.